Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier O Morales

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Antibiotics (Basel, Switzerland)|December 16, 2020
Poly-ε-caprolactone Nanoparticles Loaded with 4-Nerolidylcatechol (4-NC) for Growth Inhibition of <i>Microsporum canis</i>Vanessa Raquel Greatti, Fernando Oda, Rodrigo Sorrechia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 7, 2020
Light-induced release of the cardioprotective peptide angiotensin-(1-9) from thermosensitive liposomes with gold nanoclustersJulian Bejarano, Aldo Rojas, Andrea Ramírez-Sagredo, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Ecology|April 15, 2026
Precipitation variability interacts with mean precipitation to restructure a semiarid grassland communityJennifer A Rudgers, Laureano A Gherardi, Purbendra Yogi, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2015
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto RicoKristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 4, 2009
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infectionMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Antibiotics (Basel, Switzerland)|December 16, 2020
Poly-ε-caprolactone Nanoparticles Loaded with 4-Nerolidylcatechol (4-NC) for Growth Inhibition of <i>Microsporum canis</i>Vanessa Raquel Greatti, Fernando Oda, Rodrigo Sorrechia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2007
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyMartin Markowitz, Bach-Yen Nguyen, Eduardo Gotuzzo, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 7, 2020
Light-induced release of the cardioprotective peptide angiotensin-(1-9) from thermosensitive liposomes with gold nanoclustersJulian Bejarano, Aldo Rojas, Andrea Ramírez-Sagredo, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Human Vaccines & Immunotherapeutics|March 15, 2022
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adultsKevin L Russell, Richard E Rupp, Javier O Morales-Ramirez, et al.
Ecology|April 15, 2026
Precipitation variability interacts with mean precipitation to restructure a semiarid grassland communityJennifer A Rudgers, Laureano A Gherardi, Purbendra Yogi, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2015
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto RicoKristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 6